Cabergoline plasma concentration is increased during concomitant treatment with itraconazole

Movement Disorders

Volumn 17, Issue 6, 2002, Pages 1360-1362

  Christensen, Jakob ^a,b   Dupont, Erik ^b   Øtergaard, Karen ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cabergoline; Cytochrome P 450; Drug interactions; Itraconazole; Parkinson's disease

Indexed keywords

CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CYTOCHROME P450 3A4; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ITRACONAZOLE; SELEGILINE; SPORONOX;

ADULT; AGED; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; HUMAN; IDIOPATHIC DISEASE; MAINTENANCE DRUG DOSE; MALE; MYCOSIS; PARKINSON DISEASE; PRIORITY JOURNAL;

ADULT; AGED; ANTIFUNGAL AGENTS; ANTIPARKINSON AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ERGOLINES; FEMALE; HUMANS; ITRACONAZOLE; MALE; NEUROLOGIC EXAMINATION; ONYCHOMYCOSIS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 0036868952     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10250     Document Type: Article

References (18)

1. Fariello RG. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease. Drugs 1998:55(Suppl. 1):10-16.
2. Montastruc JL, Rascol O, Senard JM. Treatment of Parkinson's disease should begin with a dopamine agonist. Mov Disord 1999; 14:725-730.
3. Rinne UK, Bracco F. Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998;55(Suppl. 1):23-30.
4. Marsden CD. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa. Drugs 1998;55(Suppl. 1):17-22.
5. Rains CP, Bryson HM, Fitton A. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs 1995;49:255-279.
6. Wienkers L. In vitro screen for the identification of potential interactions of PNU-142779 and the major human cytochrome P450 enzymes expressed in liver. Report no. a0016932. Kalamazoo, MI: Pharmacia and Upjohn; 1998.
7. Bennett JE. Antimicrobial agents (continued). Antifungal agents. In: Hardman JG, Limbird LE, Gilman AG, editors. The pharmacological basis of therapeutics. Tenth ed. New York: McGraw-Hill: 2001. p 1295-1312.
8. De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001;61(Suppl. 1):27-37.
9. Varis T, Kivisto KT, Backman JT, Neuvonen PJ. Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. Pharmacol Toxicol 1999;85:29-32.
10. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-607.
11. Kivisto KT, Lamberg TS, Kantola T, Neuvonen PJ. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther 1997;62:348-354.
12. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997:61:410-415.
13. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60:54-61.
14. Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin. Pharmacol. Ther. 1998;64:363-368.
15. Fahn S, Elton R, Members of UPDRS Development Committee. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson's disease. Vol. 2. Florham Park, NJ: Macmillan Health Care Information; 1987. p 153-163, 293-304.
16. Renoux A, Gesson-Cholat I. Determination of the concentration of cabergoline in a single and multiple-dose pharmacokinetics evaluation study in healthy elderly and young volunteers. Report no. P99133. Kalamazoo. MI: Pharmacia and Upjohn; 2000.
17. Rahimy M, Bolyard K, Knuth D, et al. Cabergoline (PNU-124779): evaluation of single- and multiple-dose pharmacokinetics in healthy young and elderly volunteers. Report no. 779-CNS-0067-0022. Kalamazoo, MI: Pharmacia and Upjohn; 2000.
18. Kivisto KT, Wang JS, Backman JT, Nyman L, Taavitsainen P, Anttila M, Neuvonen PJ. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol 2001;57:37-42.